Developer docs
API playgroundTry for free, no card

Search company profiles

HeartBeam

Full company profile

uuid0000f3u

Namestring
HeartBeam
Legal namestring
HeartBeam, Inc.
Websiteurl
heartbeam.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

HeartBeam, Inc. is a publicly traded cardiac medical technology company (NASDAQ: BEAT) that has developed a 3D-vector electrocardiogram (VECG) platform consisting of a credit card-sized, cable-free device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix. The core FDA-cleared HeartBeam System and 12-Lead ECG Synthesis Software (cleared December 2025) are paired with a patient-facing mobile app, cloud infrastructure, and clinician portal for on-call physician review. The technology is protected by over 20 issued patents worldwide, was originated by Founder Branislav Vajdic, and is being extended through pipeline products including an on-demand 12-lead ECG patch, the HeartBeam AI deep-learning suite for arrhythmia and heart attack detection, and the acquired LIVMOR Halo+ Atrial Fibrillation Detection System.

The company operates in the cardiac diagnostics space with a primary focus on enabling clinical-grade 12-lead ECG capture outside traditional healthcare facilities. HeartBeam initially pursued direct sales into the high-value direct-pay and preventive cardiology segment through concierge and preventive cardiology practices such as ClearCardio (first commercial customer, March 2026) and Atelier Health (May 2026, covering four U.S. launch markets: New York metro, Dallas, South Florida, Southern California). In June 2026, the company announced a strategic reorganization under Founder/President Branislav Vajdic and Executive Chairman Rich Ferrari to shift from direct medical device sales to licensing its patented 3D ECG platform to established partners — governments, health systems, ECG manufacturers, and wearable device companies — across five distribution channels to accelerate global adoption.

HeartBeam's commercial economics are pre-revenue: Q1 2026 reported no recognized revenue and FY2025 showed a $21.0 million net loss. The company has funded operations through post-IPO public offerings totaling roughly $45 million since 2023 and filed a $100 million shelf registration in March 2026, with insider ownership around 18% and a market capitalization of approximately $47.25 million as of April 2026. Strategic collaborations with Mount Sinai (AI-ECG algorithm development) and AccurKardia (ECG analysis software integration) are intended to deepen the platform's clinical and AI capabilities and support combined FDA clearance paths.

Short descriptiontext

HeartBeam is a publicly traded cardiac technology company (NASDAQ: BEAT) that has developed a first-of-its-kind, credit card-sized, cable-free device (HeartBeam AIMIGo) capturing 3D ECG signals and synthesizing a 12-lead ECG for at-home arrhythmia assessment, targeting preventive cardiology, concierge medicine, and—via a June 2026 pivot—licensing to OEMs, health systems, and wearable device makers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Clara, United States
HQ citystring
Santa Clara
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac diagnostics, ECG monitoring, cardiac medical devices, heart rhythm analysis, telemedicine cardiology
Industry1 code
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Diagnostic Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware sales (commercial launch)
TypeHardware Sales
Description

HeartBeam began commercial-stage operations in early 2026 with FDA clearance of its synthesized 12-lead ECG system. Q1 2026 reported no revenue recognized, indicating commercial sales were still in early-stage ramp-up following ClearCardio as first commercial customer.

stocktitan.net
2Licensing of 3D ECG signal technology platform
TypeLicensing Royalties
Description

Following strategic reorganization in June 2026, HeartBeam is shifting from direct medical device sales to licensing its patented 3D ECG signal technology platform to established partners (governments, health systems, ECG manufacturers, wearable device companies) across five distribution channels to accelerate global adoption and reduce costs.

stocktitan.net
3Strategic collaboration / co-development revenue
TypeProfessional Services
Description

Collaboration with AccurKardia to integrate FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment, with plans for combined FDA clearance.

dicardiology.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Commercial launch with Letter of Intent structure; quote-based pricing not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Initial staged rollout with ClearCardio under Letter of Intent, with plans for broader expansion to thousands of members. Pricing is not publicly disclosed.

stocktitan.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1HeartBeam AIMIGo
Description

Credit card-sized, cable-free device that captures heart signals in three dimensions and synthesizes a 12-lead ECG for at-home arrhythmia assessment.

heartbeam.com
+3 more records
Core offering1 text field

HeartBeam develops a cable-free, credit-card-sized ECG device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix, paired with a cloud platform, patient-facing mobile app, and clinician portal for at-home arrhythmia assessment. The FDA-cleared core platform is being expanded into heart attack (ischemia) detection and licensed to OEMs/wearable device makers under a 2026 strategic shift.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 86.5% AUC for heart attack detection with a single reading; 92.9% AUC when baseline ECG was available (184-patient study published in JACC: Advances)
+4 more records
Product overview1 text field

HeartBeam offers an integrated cardiac care platform built around a single FDA-cleared core hardware device (the HeartBeam System) paired with its companion 12-Lead ECG Synthesis Software, delivered primarily through the credit card-sized portable HeartBeam AIMIGo device. The system architecture combines the hardware recorder (capturing 3-Lead ECG from three directions via 5 electrodes), cloud synthesis (personalized transformation matrix producing a synthesized 12-Lead ECG), the patient-facing mobile app, and the clinician portal for manual interpretation. Acquired assets (the LIVMOR Halo+ Atrial Fibrillation Detection System) extend remote monitoring reach. Pipeline offerings include the investigational extended-wear 12-Lead ECG Patch, the HeartBeam AI deep-learning capabilities (atrial fibrillation/flutter detection), and the Ischemia Detection Product targeting heart attack assessment.

Product and service5 records
1HeartBeam AIMIGo
CategoryAmbulatory Cardiac Monitoring Device
Description

A credit card-sized, portable, cable-free device that captures the heart's electrical signals from three dimensions and synthesizes a 12-lead ECG using a personalized transformation matrix. The patient places the device on the chest for a 30-second recording that is sent to the cloud for on-call cardiologist review.

2HeartBeam 12-Lead ECG Synthesis Software
CategoryECG Analysis Software
Description

Software that synthesizes a 12-Lead ECG from the HeartBeam System's 3-Lead (in three-directions) recording using a personalized transformation matrix, producing a visual 12-Lead ECG for manual assessment of non-life-threatening arrhythmias by a physician or healthcare professional.

3HeartBeam System (3-Lead ECG Recorder)
CategoryCardiac Recording Device
Description

A portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) ECG acquired from 5 electrodes, used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation.

4Halo+ Atrial Fibrillation Detection System
CategoryRemote Cardiac Monitoring System
Description

An FDA-cleared remote monitoring system for physiological markers with atrial fibrillation detection capability, acquired from LIVMOR along with related patents, technology, business contracts, and inventory.

5HeartBeam AIMI
CategoryAcute Care ECG Software
Description

Software designed for acute care settings that compares ECGs to identify heart attacks. Patented product in regulatory resubmission for remote cardiac evaluation in acute care environments.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Atelier Health
TypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-07
Description

Commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center, to offer HeartBeam's cable-free 3D ECG technology to patients. Expands commercial footprint across four targeted U.S. launch markets: New York metro, Dallas, South Florida, and Southern California, completing initial geographic foundation for scalable growth.

stocktitan.net
TypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Mentioned in coverage of decentralized AI in cardiac diagnostics: VentriPoint Diagnostics partnered with First Light Health to deploy AI-powered cardiac diagnostics using VentriPoint's VMS+ system in remote and Indigenous communities across Canada. HeartBeam mentioned alongside as developing AI-enabled cardiac diagnostics. (Indirect context; HeartBeam parallel developments referenced.)

TypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Strategic AI collaboration to develop advanced AI-ECG algorithms, integrating Mount Sinai's clinical expertise with HeartBeam's 3D ECG technology. The partnership aims to develop a new platform capable of collecting 12-lead ECG data from patients at home, enabling scalable, personalized cardiac health assessments in real-world settings and supporting broader applications in preventive cardiology and chronic disease management.

TypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Strategic collaboration to develop cardiac monitoring solutions by integrating AccurKardia's FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment and expedited cardiac diagnosis. Plans include joint FDA clearance efforts. Earlier reported on prlog (2026-04-21) as forming a collaboration to enhance cardiac monitoring through ambulatory ECG recording and analysis.

TypeStrategic or Co-development PartnerAnnounced on2023-03-14
Description

HeartBeam acquired substantially all assets of LIVMOR, including the FDA-cleared Halo+ Atrial Fibrillation Detection System, related technology, patents, business contracts, inventory, and key technical staff. The acquisition built on a 2022 partnership between HeartBeam and LIVMOR to develop HeartBeam-branded versions of LIVMOR's cardio health software platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

iRhythm's Zio long-term continuous ambulatory ECG monitor competes in the same remote cardiac monitoring category as HeartBeam's investigational extended-wear patch and arrhythmia assessment platform.

TypeDirect peer
Description

AliveCor makes KardiaMobile, a consumer/clinical single-lead ECG device paired with AI-based arrhythmia detection. Directly comparable as a portable, patient-facing ECG platform targeting arrhythmia assessment outside the clinic, and a former employer of HeartBeam's CCO.

TypeBroad incumbent
Description

Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitoring (patch and event monitor) for ambulatory arrhythmia detection — directly comparable in use case and overlaps with HeartBeam's extended-wear patch and ambulatory ECG ambitions.

TypeBroad incumbent
Description

Apple Watch offers FDA-cleared single-lead ECG and AFib detection features to a massive consumer installed base. While limited to single-lead and consumer use, it sets expectations for at-home ECG and is a frequent reference point in HeartBeam's competitive positioning.

TypeDirect peer
Description

Eko Health builds digital stethoscopes with embedded ECG and AI algorithms for cardiac and pulmonary assessment. Comparable as a portable AI-ECG platform aimed at clinicians and remote monitoring, and also a former employer of HeartBeam's CCO.

TypeEmerging player
Description

HeartFlow offers AI-driven non-invasive cardiac diagnostics (FFR-CT for coronary disease). Comparable as a technology-enabled cardiac diagnostics company focused on actionable clinical insights, and a former employer of HeartBeam's CCO.

TypeEmerging player
Description

Cardiac Insight provides the Cardea SOLO wearable ECG sensor and automated arrhythmia analysis software for ambulatory cardiac screening. Comparable as a smaller, ambulatory, AI-ECG player in the same patient-monitoring category as HeartBeam.

TypeBroad incumbent
Description

GE HealthCare manufactures resting ECG, stress, and Holter monitoring systems used in hospitals and clinics. Comparable as a broad incumbent ECG vendor and a potential licensing/OEM partner for HeartBeam's 3D ECG signal platform.

TypeEmerging player
Description

AccurKardia develops FDA-cleared ECG analysis software for automated rhythm assessment. Already a strategic partner of HeartBeam for integrated rhythm analysis, and closely comparable as an AI-ECG software platform with overlapping arrhythmia detection IP.

TypeBroad incumbent
Description

Philips provides a broad portfolio of resting ECG, Holter, and remote cardiac monitoring solutions (including the recently divested BioTelemetry assets). Comparable as an established multi-channel ECG and cardiac monitoring vendor that HeartBeam could partner with or compete against under the licensing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HeartBeam

Cardiac Diagnostic Devicesheartbeam.com

HeartBeam is a publicly traded cardiac technology company (NASDAQ: BEAT) that has developed a first-of-its-kind, credit card-sized, cable-free device (HeartBeam AIMIGo) capturing 3D ECG signals and synthesizing a 12-lead ECG for at-home arrhythmia assessment, targeting preventive cardiology, concierge medicine, and—via a June 2026 pivot—licensing to OEMs, health systems, and wearable device makers.

What HeartBeam does

HeartBeam, Inc. is a publicly traded cardiac medical technology company (NASDAQ: BEAT) that has developed a 3D-vector electrocardiogram (VECG) platform consisting of a credit card-sized, cable-free device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix. The core FDA-cleared HeartBeam System and 12-Lead ECG Synthesis Software (cleared December 2025) are paired with a patient-facing mobile app, cloud infrastructure, and clinician portal for on-call physician review. The technology is protected by over 20 issued patents worldwide, was originated by Founder Branislav Vajdic, and is being extended through pipeline products including an on-demand 12-lead ECG patch, the HeartBeam AI deep-learning suite for arrhythmia and heart attack detection, and the acquired LIVMOR Halo+ Atrial Fibrillation Detection System.

The company operates in the cardiac diagnostics space with a primary focus on enabling clinical-grade 12-lead ECG capture outside traditional healthcare facilities. HeartBeam initially pursued direct sales into the high-value direct-pay and preventive cardiology segment through concierge and preventive cardiology practices such as ClearCardio (first commercial customer, March 2026) and Atelier Health (May 2026, covering four U.S. launch markets: New York metro, Dallas, South Florida, Southern California). In June 2026, the company announced a strategic reorganization under Founder/President Branislav Vajdic and Executive Chairman Rich Ferrari to shift from direct medical device sales to licensing its patented 3D ECG platform to established partners — governments, health systems, ECG manufacturers, and wearable device companies — across five distribution channels to accelerate global adoption.

HeartBeam's commercial economics are pre-revenue: Q1 2026 reported no recognized revenue and FY2025 showed a $21.0 million net loss. The company has funded operations through post-IPO public offerings totaling roughly $45 million since 2023 and filed a $100 million shelf registration in March 2026, with insider ownership around 18% and a market capitalization of approximately $47.25 million as of April 2026. Strategic collaborations with Mount Sinai (AI-ECG algorithm development) and AccurKardia (ECG analysis software integration) are intended to deepen the platform's clinical and AI capabilities and support combined FDA clearance paths.

HeartBeam firmographics

Firmographics
Name
HeartBeam
Legal name
HeartBeam, Inc.
Website
https://heartbeam.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
HeartBeam is a publicly traded cardiac technology company (NASDAQ: BEAT) that has developed a first-of-its-kind, credit card-sized, cable-free device (HeartBeam AIMIGo) capturing 3D ECG signals and synthesizing a 12-lead ECG for at-home arrhythmia assessment, targeting preventive cardiology, concierge medicine, and—via a June 2026 pivot—licensing to OEMs, health systems, and wearable device makers.
Ownership category
akta.pro rank

HeartBeam industry classification

Industry
Product category
Cardiac Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Cardiac diagnostics
  • ECG monitoring
  • Cardiac medical devices
  • Heart rhythm analysis
  • Telemedicine cardiology

Where HeartBeam is headquartered

Location

Headquarters

HQ city
Santa Clara
HQ country
United States
HQ region
North America

Offices2 records

Markets served

HeartBeam business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Hardware sales (commercial launch): HeartBeam began commercial-stage operations in early 2026 with FDA clearance of its synthesized 12-lead ECG system. Q1 2026 reported no revenue recognized, indicating commercial sales were still in early-stage ramp-up following ClearCardio as first commercial customer.
  2. Licensing of 3D ECG signal technology platform: Following strategic reorganization in June 2026, HeartBeam is shifting from direct medical device sales to licensing its patented 3D ECG signal technology platform to established partners (governments, health systems, ECG manufacturers, wearable device companies) across five distribution channels to accelerate global adoption and reduce costs.
  3. Strategic collaboration / co-development revenue: Collaboration with AccurKardia to integrate FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment, with plans for combined FDA clearance.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCommercial launch with Letter of Intent structure; quote-based pricing not publicly disclosed

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

HeartBeam product offering

Product offering

Core offering

HeartBeam develops a cable-free, credit-card-sized ECG device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix, paired with a cloud platform, patient-facing mobile app, and clinician portal for at-home arrhythmia assessment. The FDA-cleared core platform is being expanded into heart attack (ischemia) detection and licensed to OEMs/wearable device makers under a 2026 strategic shift.

Product overview

HeartBeam offers an integrated cardiac care platform built around a single FDA-cleared core hardware device (the HeartBeam System) paired with its companion 12-Lead ECG Synthesis Software, delivered primarily through the credit card-sized portable HeartBeam AIMIGo device. The system architecture combines the hardware recorder (capturing 3-Lead ECG from three directions via 5 electrodes), cloud synthesis (personalized transformation matrix producing a synthesized 12-Lead ECG), the patient-facing mobile app, and the clinician portal for manual interpretation. Acquired assets (the LIVMOR Halo+ Atrial Fibrillation Detection System) extend remote monitoring reach. Pipeline offerings include the investigational extended-wear 12-Lead ECG Patch, the HeartBeam AI deep-learning capabilities (atrial fibrillation/flutter detection), and the Ischemia Detection Product targeting heart attack assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • HeartBeam AIMIGo: Credit card-sized, cable-free device that captures heart signals in three dimensions and synthesizes a 12-lead ECG for at-home arrhythmia assessment.
  • HeartBeam AIMI
  • HeartBeam System
  • HeartBeam 12-Lead ECG Synthesis Software

Products and services

  • HeartBeam AIMIGo A credit card-sized, portable, cable-free device that captures the heart's electrical signals from three dimensions and synthesizes a 12-lead ECG using a personalized transformation matrix. The patient places the device on the chest for a 30-second recording that is sent to the cloud for on-call cardiologist review.
  • HeartBeam 12-Lead ECG Synthesis Software Software that synthesizes a 12-Lead ECG from the HeartBeam System's 3-Lead (in three-directions) recording using a personalized transformation matrix, producing a visual 12-Lead ECG for manual assessment of non-life-threatening arrhythmias by a physician or healthcare professional.
  • HeartBeam System (3-Lead ECG Recorder) A portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) ECG acquired from 5 electrodes, used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation.
  • Halo+ Atrial Fibrillation Detection System An FDA-cleared remote monitoring system for physiological markers with atrial fibrillation detection capability, acquired from LIVMOR along with related patents, technology, business contracts, and inventory.
  • HeartBeam AIMI Software designed for acute care settings that compares ECGs to identify heart attacks. Patented product in regulatory resubmission for remote cardiac evaluation in acute care environments.

Quantifiable outcome

  • 86.5% AUC for heart attack detection with a single reading; 92.9% AUC when baseline ECG was available (184-patient study published in JACC: Advances)
  • +4 more outcomes

Companies that use HeartBeam

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles5 records

HeartBeam technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature8 records

HeartBeam partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record.

  • Atelier HealthChannel Partner/ Reseller/ Distributor · 7 May 2026Commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center, to offer HeartBeam's cable-free 3D ECG technology to patients. Expands commercial footprint across four targeted U.S. launch markets: New York metro, Dallas, South Florida, and Southern California, completing initial geographic foundation for scalable growth.
  • VentriPoint Diagnostics / First Light HealthStrategic or Co-development Partner · 27 March 2026Mentioned in coverage of decentralized AI in cardiac diagnostics: VentriPoint Diagnostics partnered with First Light Health to deploy AI-powered cardiac diagnostics using VentriPoint's VMS+ system in remote and Indigenous communities across Canada. HeartBeam mentioned alongside as developing AI-enabled cardiac diagnostics. (Indirect context; HeartBeam parallel developments referenced.)
  • Mount SinaiStrategic or Co-development Partner · 10 March 2026Strategic AI collaboration to develop advanced AI-ECG algorithms, integrating Mount Sinai's clinical expertise with HeartBeam's 3D ECG technology. The partnership aims to develop a new platform capable of collecting 12-lead ECG data from patients at home, enabling scalable, personalized cardiac health assessments in real-world settings and supporting broader applications in preventive cardiology and chronic disease management.
  • AccurKardiaStrategic or Co-development Partner · 28 April 2025Strategic collaboration to develop cardiac monitoring solutions by integrating AccurKardia's FDA-cleared ECG analysis software into HeartBeam's device for automated rhythm assessment and expedited cardiac diagnosis. Plans include joint FDA clearance efforts. Earlier reported on prlog (2026-04-21) as forming a collaboration to enhance cardiac monitoring through ambulatory ECG recording and analysis.
  • LIVMOR, Inc.Strategic or Co-development Partner · 14 March 2023HeartBeam acquired substantially all assets of LIVMOR, including the FDA-cleared Halo+ Atrial Fibrillation Detection System, related technology, patents, business contracts, inventory, and key technical staff. The acquisition built on a 2022 partnership between HeartBeam and LIVMOR to develop HeartBeam-branded versions of LIVMOR's cardio health software platform.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

HeartBeam competitors and assessment

Company assessment

Direct peers

  • iRhythm Technologies: iRhythm's Zio long-term continuous ambulatory ECG monitor competes in the same remote cardiac monitoring category as HeartBeam's investigational extended-wear patch and arrhythmia assessment platform.
  • AliveCor: AliveCor makes KardiaMobile, a consumer/clinical single-lead ECG device paired with AI-based arrhythmia detection. Directly comparable as a portable, patient-facing ECG platform targeting arrhythmia assessment outside the clinic, and a former employer of HeartBeam's CCO.
  • Eko Health: Eko Health builds digital stethoscopes with embedded ECG and AI algorithms for cardiac and pulmonary assessment. Comparable as a portable AI-ECG platform aimed at clinicians and remote monitoring, and also a former employer of HeartBeam's CCO.

Broad incumbents

  • Preventice Solutions (Boston Scientific): Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitoring (patch and event monitor) for ambulatory arrhythmia detection — directly comparable in use case and overlaps with HeartBeam's extended-wear patch and ambulatory ECG ambitions.
  • Apple (Apple Watch ECG): Apple Watch offers FDA-cleared single-lead ECG and AFib detection features to a massive consumer installed base. While limited to single-lead and consumer use, it sets expectations for at-home ECG and is a frequent reference point in HeartBeam's competitive positioning.
  • GE HealthCare: GE HealthCare manufactures resting ECG, stress, and Holter monitoring systems used in hospitals and clinics. Comparable as a broad incumbent ECG vendor and a potential licensing/OEM partner for HeartBeam's 3D ECG signal platform.
  • Philips (Cardiac Monitoring): Philips provides a broad portfolio of resting ECG, Holter, and remote cardiac monitoring solutions (including the recently divested BioTelemetry assets). Comparable as an established multi-channel ECG and cardiac monitoring vendor that HeartBeam could partner with or compete against under the licensing model.

Emerging players

  • HeartFlow: HeartFlow offers AI-driven non-invasive cardiac diagnostics (FFR-CT for coronary disease). Comparable as a technology-enabled cardiac diagnostics company focused on actionable clinical insights, and a former employer of HeartBeam's CCO.
  • Cardiac Insight: Cardiac Insight provides the Cardea SOLO wearable ECG sensor and automated arrhythmia analysis software for ambulatory cardiac screening. Comparable as a smaller, ambulatory, AI-ECG player in the same patient-monitoring category as HeartBeam.
  • AccurKardia: AccurKardia develops FDA-cleared ECG analysis software for automated rhythm assessment. Already a strategic partner of HeartBeam for integrated rhythm analysis, and closely comparable as an AI-ECG software platform with overlapping arrhythmia detection IP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

HeartBeam social profiles

Digital presence

HeartBeam compliance and trust

Trust signal

Compliance1 record

HeartBeam financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HeartBeam leadership team

Management profile

Number of profiles

Profiles8 records

HeartBeam subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HeartBeam funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HeartBeam M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HeartBeam

What does HeartBeam do?

HeartBeam develops a cable-free, credit-card-sized ECG device (HeartBeam AIMIGo) that captures the heart's electrical signals from three non-orthogonal directions and synthesizes a full 12-lead ECG using a personalized transformation matrix, paired with a cloud platform, patient-facing mobile app, and clinician portal for at-home arrhythmia assessment. The FDA-cleared core platform is being expanded into heart attack (ischemia) detection and licensed to OEMs/wearable device makers under a 2026 strategic shift.

Is HeartBeam a public or private company?

HeartBeam is a public company. It is classified as public and is currently operating.

When was HeartBeam founded?

HeartBeam was founded in 2015. It employs 11 to 50 people.

Where is HeartBeam based?

HeartBeam is headquartered in Santa Clara, United States, in the North America region.

How does HeartBeam make money?

Three revenue lines are on record. Hardware sales (commercial launch) is the primary driver. The others are licensing of 3D ECG signal technology platform and strategic collaboration / co-development revenue.

Who are HeartBeam's main competitors?

Direct peers on record are iRhythm Technologies, AliveCor and Eko Health. Broad incumbents are Preventice Solutions (Boston Scientific), Apple (Apple Watch ECG), GE HealthCare and Philips (Cardiac Monitoring). Emerging players are HeartFlow, Cardiac Insight and AccurKardia.

Does HeartBeam have an API?

No public API is recorded for HeartBeam.

What industry is HeartBeam in?

HeartBeam's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialInvestornewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Reports Narrower Q3 Net Loss, Advances Heart Attack Assessment ProgramHeartBeam Inc. reported a narrower Q3 net loss and received FDA Breakthrough Device Designation for its heart attack assessment program. The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from a 132-patient pilot study showing higher specificity than standard 12-lead ECGs. It plans to finalize its U.S. pivotal study design in Q4 2026 and begin enrollment in Q1 2027.YahooHeartBeam Inc (BEAT) (Q3 2026) Earnings Call Highlights: FDA Breakthrough Status, ALIGN ACS ...HeartBeam Inc reported FDA Breakthrough Device Designation and TAP program entry, with its 3D ECG showing higher specificity (81.8% vs 71.4%) in the ALIGN ACS study. Q3 operating cash outflow fell 23% sequentially to $2.6 million, extending cash runway into 2027. The company faces a Nasdaq compliance deadline of December 28, 2026, and expects pivotal study enrollment in Q1 2027.Defense WorldHeartBeam (BEAT) Expected to Post Quarterly Earnings on ThursdayHeartBeam is expected to report Q3 2026 earnings after market close on November 12, 2026, with analysts projecting a loss of $0.09 per share and revenue of $0.08 million. The stock opened at $0.41, and analysts have an average rating of Moderate Buy with a consensus price target of $4.00.American Banking and Market NewsHeartBeam (BEATW) Projected to Announce Quarterly Earnings on ThursdayHeartBeam is expected to announce quarterly earnings after market close on Thursday, November 5th. Analysts project a loss of $0.09 per share and revenue of $0.07 million. The stock opened at $0.01, with a 52-week range of $0.00 to $0.56.FinancialContent Business PageMissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2026 Financial Results Conference Call for Nov. 12HeartBeam Inc. will hold a conference call on Nov. 12, 2026, to discuss Q3 2026 financial results. Management will also present updates on the ALIGN-ACS pilot study and upcoming milestones for its Heart Attack Detection program. A press release will be issued before the call.Business & FinancialMissionirnewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Reports Positive ALIGN-ACS Pilot Study Results For Heart Attack Assessment TechnologyHeartBeam Inc. reported positive results from its ALIGN-ACS pilot study, showing greater consistency among cardiologists interpreting HeartBeam recordings compared with standard ECGs. The company plans a U.S. pivotal study in the first quarter of 2027 to support an FDA submission to expand its indication beyond arrhythmia assessment to include heart attack assessment.The future of tradingHeartBeam Plans ALIGN-ACS Heart Attack Assessment Study Results Presentation at TCTHeartBeam will present its ALIGN-ACS heart attack assessment study results at TCT 2026 on November 1. The 132-patient pilot compared its 3D ECG technology with standard 12-lead ECG for detecting acute coronary syndrome.Business Wire BlogHeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026HeartBeam will present results of its ALIGN-ACS pilot study comparing its 3D ECG to a standard 12-lead ECG for acute coronary syndrome detection at TCT 2026. The study enrolled 132 patients in Serbia, and results will inform the design of a U.S. pivotal study anticipated in Q1 2027.Business & FinancialAinewsbreaks Heartbeam Inc. (NASDAQ: BEAT) To Present Heart Attack Detection Pilot Study Results At TCT 2026HeartBeam Inc. will present heart attack detection pilot study results at TCT 2026, with founder Branislav Vajdic calling it an important step against conventional ECG systems. The technology holds FDA Breakthrough Device Designation and a pivotal study is anticipated to begin in Q1 2027.Business Wire BlogHeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk PatientsHeartBeam joined the EU-funded EXIT-CVD research consortium, led by University Medical Center Groningen and Philips, to advance at-home ECG monitoring for early detection of acute coronary syndrome. It will lead the HEART-CHECK study, evaluating its 3D ECG system in high-risk patients recently discharged after ACS. The system is currently FDA cleared for arrhythmia assessment only, with heart attack assessment investigational.